Skip to content
Dosage GuideResearch Reference

Kisspeptin-54 Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for Kisspeptin-54. All information is for educational purposes only.

Quick Answer

In clinical research, Kisspeptin-54 is typically administered via intravenous or subcutaneous injection. Doses range from 0.5 mcg/kg to 2.5 mcg/kg, with frequency depending on the specific application (e.g., single bolus for oocyte maturation trigger, pulsatile administration for hypogonadism). Due to its short half-life, continuous infusion or pulsatile dosing regimens are often employed. Human dose-ranging trials are still underway, and specific clinical protocols vary.

→ Kisspeptin-54 Benefits→ Kisspeptin-54 Side Effects→ Full Kisspeptin-54 Profile
Table of Contents

Standard Dosage Range

Research dosing range: 0.5–2.5 mcg/kg per dose (IV/SC)

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Oocyte Maturation Trigger (IVF)

1.0–1.5 mcg/kgSingle bolus injection
Duration

Single administration

Administered intravenously to trigger oocyte maturation in IVF cycles. Clinical trials demonstrate a significantly lower risk of ovarian hyperstimulation syndrome (OHSS) compared to hCG.

Hypogonadotropic Hypogonadism

0.5–2.0 mcg/kgPulsatile IV/SC every 1-3 hours or continuous infusion
Duration

Days to weeks (under medical supervision)

Administered intravenously or subcutaneously, often in a pulsatile fashion to mimic natural GnRH secretion. Requires close monitoring by a physician due to potential hormonal fluctuations.

Diagnostic Testing (Kisspeptin Challenge)

1.0 mcg/kgSingle bolus injection
Duration

Single administration

Used as a diagnostic tool to differentiate between hypothalamic and pituitary causes of hypogonadism. LH and FSH levels are measured before and after kisspeptin administration.

Timing & Frequency

For oocyte maturation, Kisspeptin-54 is administered as a single bolus injection at the time of trigger. For pulsatile administration in hypogonadism, the timing of doses is crucial and must be determined by a physician based on individual patient needs. The short half-life necessitates frequent dosing or continuous infusion.

Cycle Guidance

Due to the relatively new clinical applications of Kisspeptin-54, specific cycle guidance is limited. Administration is typically under the direct supervision of a medical professional specializing in reproductive endocrinology. Long-term safety and efficacy data are still being collected.

Reconstitution Reference

Quick reference for reconstituting Kisspeptin-54. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeVaries (typically 50 mcg to 1 mg per vial)
BAC Water VolumeFollow manufacturer instructions for the specific vial size to achieve the desired concentration.
Concentration & DrawConcentration will vary depending on the vial size and volume of bacteriostatic water used. Consult the product insert for specific instructions.
StorageRefrigerate at 2–8°C after reconstitution. Keep lyophilized powder at -20°C.
StabilityReconstituted solution should be used within the timeframe specified by the manufacturer (typically a few days). Lyophilized powder is stable for several months when stored properly.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the typical dose of Kisspeptin-54 for IVF?
Clinical trials have used doses ranging from 1.0 to 1.5 mcg/kg as a single bolus intravenous injection to trigger oocyte maturation in IVF cycles.
How is Kisspeptin-54 administered for hypogonadism?
For hypogonadism, Kisspeptin-54 is typically administered intravenously or subcutaneously in a pulsatile fashion or as a continuous infusion. The specific dosing regimen is determined by a physician.
What are the potential risks associated with Kisspeptin-54?
While Kisspeptin-54 has shown a lower risk of OHSS compared to hCG, potential side effects can include nausea, headache, and injection site reactions. Long-term effects are still being studied.

Last updated: 2026-02-19